Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BaroFold, a biopharmaceutical company, has appointed William Freytag as its new president and CEO.
Subscribe to our email newsletter
As BaroFold’s new president and CEO, Dr Freytag brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Dr Freytag served as chairman and CEO of Aspreva Pharmaceuticals.
Dr Freytag currently serves as the chairman of the board for BiOptix and is also serving on the board of directors of GlobeImmune, Sierra Neuropharmaceuticals, and Arca Biopharma. Dr Freytag has earned his PhD in biochemistry from the University of Kansas Medical Center.
Kyle Lefkoff, chairman of board of directors at BaroFold, said: “We are delighted to attract a leader with such an outstanding record of success. BaroFold is making excellent progress on the development of its pipeline of protein therapeutics, and Bill’s exceptional track record will help capitalize on our opportunity to make BaroFold a leading company in the fast emerging BioBetter protein therapeutic field.”